-
Tytuł:
-
Jumonji domain-containing protein 6 functions as a marker of head and neck squamous cell carcinoma at advanced stage with no effect on prognosis.
-
Autorzy:
-
Guo B; Department of Oral and Maxillofacial, Head and Neck Oncology, 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology, Shanghai 200011, P.R. China.
Wang L; Department of Oral and Maxillofacial, Head and Neck Oncology, 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology, Shanghai 200011, P.R. China.
Qin X; Department of Oral and Maxillofacial, Head and Neck Oncology, 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology, Shanghai 200011, P.R. China.
Shen Y; Department of Oral and Maxillofacial, Head and Neck Oncology, 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology, Shanghai 200011, P.R. China.
Ma C; Department of Oral and Maxillofacial, Head and Neck Oncology, 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology, Shanghai 200011, P.R. China.
-
Źródło:
-
Oncology letters [Oncol Lett] 2019 Dec; Vol. 18 (6), pp. 5843-5852. Date of Electronic Publication: 2019 Sep 30.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [Athens : Spandidos Publications]
-
References:
-
Front Genet. 2017 Mar 16;8:32. (PMID: 28360925)
J Exp Clin Cancer Res. 2018 Jul 9;37(1):143. (PMID: 29986759)
Annu Rev Pathol. 2018 Jan 24;13:395-412. (PMID: 29414248)
Nucleic Acids Res. 2016 Dec 15;44(22):10662-10675. (PMID: 27613418)
PLoS Biol. 2014 Mar 25;12(3):e1001819. (PMID: 24667498)
Clin Epigenetics. 2016 Apr 14;8:38. (PMID: 27081402)
J Biol Chem. 2013 Mar 1;288(9):6053-62. (PMID: 23303181)
Carcinogenesis. 2016 Feb;37(2):119-128. (PMID: 26645717)
Breast Cancer Res. 2012 May 23;14(3):R85. (PMID: 22621393)
Mol Cancer. 2017 Nov 29;16(1):175. (PMID: 29187213)
Nucleic Acids Res. 2017 Apr 7;45(6):3503-3518. (PMID: 27899633)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Clin Cancer Res. 2019 Jul 15;25(14):4211-4223. (PMID: 30814108)
CA Cancer J Clin. 2017 Mar;67(2):122-137. (PMID: 28128848)
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102. (PMID: 28407145)
Sci Rep. 2017 Nov 24;7(1):16272. (PMID: 29176719)
Int J Cancer. 2019 May 15;144(10):2489-2500. (PMID: 30125344)
Oncogene. 2019 Feb;38(7):980-997. (PMID: 30185813)
Nat Methods. 2009 Apr;6(4):239-40. (PMID: 19333237)
Nucleic Acids Res. 2015 Jan;43(Database issue):D812-7. (PMID: 25392408)
-
Contributed Indexing:
-
Keywords: Jumonji domain-containing protein 6; epithelial- mesenchymal transition; head and neck squamous cell carcinoma; malignant progression; prognosis
-
Entry Date(s):
-
Date Created: 20191203 Latest Revision: 20200928
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC6865058
-
DOI:
-
10.3892/ol.2019.10938
-
PMID:
-
31788057
-
A number of studies have reported the upregulation and functional roles of Jumonji domain-containing protein 6 (JMJD6) in various types of cancer. However, little is known regarding the clinical significance of JMJD6 in head and neck squamous cell carcinoma (HNSCC), particularly in terms of large-cohort data. In the present study, bioinformatics analysis was performed, using the University of California Santa Cruz Xena Browser and the Gene Expression Profiling Interactive Analysis 2 server, based on the Cancer Genome Atlas HNSCC cohort. In addition, a validation cohort was constructed based on 98 HNSCC cases. JMJD6 overexpression and knockdown, colony-formation, Transwell and cell viability assays were performed. JMJD6 was highly expressed in HNSCC samples and was associated with advanced pathological stage. However, no significant association was observed between JMJD6 expression levels and overall survival or disease-free survival times of patients with HNSCC. Subsequent in vitro assays indicated that overexpression of JMJD6 promoted malignant progression of HNSCC, by regulating epithelial-mesenchymal transition. Nevertheless, JMJD6 overexpression had no significant effects on the viability of HNSCC cells treated with 5-fluorouracil or cisplatin. Thus, it can be concluded that JMJD6 may function as a marker of HNSCC at advanced stage, however with no effect on drug resistance or prognosis. For patients with advanced HNSCC and high JMJD6 expression, rational chemotherapy may be more beneficial than radical surgery, considering their quality of life.
(Copyright: © Guo et al.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.
